Literature DB >> 6446228

Dimaprit inhibition of zymosan-stimulated beta-glucuronidase release from human granulocytes.

W W Busse, W Cooper, C Anderson.   

Abstract

Histamine inhibits the in vitro release of granulocytic lysosomal beta-glucuronidase when incubated with complement activated zymosan particles and this is an H2-receptor response. The highly specific histamine H2-receptor agonist, dimaprit, also inhibits this secretory enzyme release but is less potent (-log molar ED50 6.71 with histamine vs. -log ED50 5.97 with dimaprit, p less than 0.05). No change in beta-glucuronidase release was found with the H1-agonst, 2-(2 pyridyl)-ethylamine. The antagonist activity of metiamide was similar with the two agonists (KB = 2.9 x 10(-8) M with histamine and KB = 3.6 x 10(-8) M with dimaprit). Diphenhydramine did not change the granulocyte response to either histamine or dimaprit.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6446228     DOI: 10.1007/bf02024173

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  15 in total

1.  Enzyme release from polymorphonuclear leukocyte lysosomes: regulation by autonomic drugs and cyclic nucleotides.

Authors:  L J Ignarro; C Colombo
Journal:  Science       Date:  1973-06-15       Impact factor: 47.728

2.  Definition and antagonism of histamine H 2 -receptors.

Authors:  J W Black; W A Duncan; C J Durant; C R Ganellin; E M Parsons
Journal:  Nature       Date:  1972-04-21       Impact factor: 49.962

3.  Receptors mediating some actions of histamine.

Authors:  A S Ash; H O Schild
Journal:  Br J Pharmacol Chemother       Date:  1966-08

4.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

5.  The immunologic release of constituents from neutrophil leukocytes. I. The role of antibody and complement on nonphagocytosable surfaces or phagocytosable particles.

Authors:  P M Henson
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

6.  The pharmacological differentiation of adrenergic receptors.

Authors:  R F Furchgott
Journal:  Ann N Y Acad Sci       Date:  1967-02-10       Impact factor: 5.691

7.  Human serum beta-glucuronidase; its measurement and some of its properties.

Authors:  W H Fishman; K Kato; C L Anstiss; S Green
Journal:  Clin Chim Acta       Date:  1967-03       Impact factor: 3.786

8.  Decreased H2 histamine response of granulocytes of asthmatic patients.

Authors:  W W Busse; J Sosman
Journal:  J Clin Invest       Date:  1977-06       Impact factor: 14.808

9.  Mechanisms of lysosomal enzyme release from human leukocytes. II. Effects of cAMP and cGMP, autonomic agonists, and agents which affect microtubule function.

Authors:  R B Zurier; G Weissmann; S Hoffstein; S Kammerman; H H Tai
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

10.  Histamine inhibition of neutrophil lysosomal enzyme release: an H2 histamine receptor response.

Authors:  W W Busse; J Sosman
Journal:  Science       Date:  1976-11-12       Impact factor: 47.728

View more
  3 in total

1.  Histamine-induced inhibition of lymphocyte proliferation and lysosomal enzyme release from polymorphs may not be mediated via H1- or H2-receptors.

Authors:  M R Vickers; K Milliner; D Martin; C R Ganellin
Journal:  Agents Actions       Date:  1982-12

2.  Histamine-induced inhibition of leukotriene biosynthesis in human neutrophils: involvement of the H2 receptor and cAMP.

Authors:  Nicolas Flamand; Hendrick Plante; Serge Picard; Michel Laviolette; Pierre Borgeat
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

3.  Autacoid and beta-adrenergic agonist modulation of N-formylmethionyl-leucyl-phenylalanine evoked lysosomal enzyme release from human neutrophils.

Authors:  R Fantozzi; S Brunelleschi; S Cambi; P Blandina; E Masini; P F Mannaioni
Journal:  Agents Actions       Date:  1984-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.